Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity: 2021-2025

Historic Liabilities and Shareholders Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $13.4 million.

  • InMed Pharmaceuticals' Liabilities and Shareholders Equity rose 27.67% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 8.21%. This contributed to the annual value of $15.6 million for FY2025, which is 31.78% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Liabilities and Shareholders Equity of $13.4 million as of Q3 2025, which was down 14.24% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $19.4 million during Q4 2021, and its lowest value of $8.5 million during Q4 2024.
  • Over the past 3 years, InMed Pharmaceuticals' median Liabilities and Shareholders Equity value was $13.4 million (recorded in 2024), while the average stood at $12.5 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 44.27% in 2024, then spiked by 31.78% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Liabilities and Shareholders Equity stood at $19.4 million in 2021, then dropped by 12.71% to $16.9 million in 2022, then fell by 9.84% to $15.3 million in 2023, then tumbled by 44.27% to $8.5 million in 2024, then rose by 27.67% to $13.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $13.4 million in Q3 2025, compared to $15.6 million in Q2 2025 and $9.3 million in Q1 2025.